FindTrial
Sign In

A prospective multicenter clinical study of relapsed acute promyelocytic leukemia in children (SCCCG R-APL 2023 protocol)

A prospective multicenter clinical study of relapsed acute promyelocytic leukemia in children (SCCCG R-APL 2023 protocol)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074053
Enrollment
Unknown
Registered
2023-07-28
Start date
2023-08-01
Completion date
Unknown
Last updated
2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed acute promyelocytic leukemia

Interventions

Relapsed acute promyelocytic leukemia in children (Treatment was performed with the SCCCG R-APL 2023 protocol):NA

Sponsors

The First Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Children <18 years old;PML-RARa/t(15;17) Positive patients with recurrent acute promyelocytic leukemia

Exclusion criteria

Exclusion criteria: Patients were not treated with multi-center SCCCG R-APL 2023 protocol

Design outcomes

Primary

MeasureTime frame
5-year event-free survival;—

Secondary

MeasureTime frame
5-year recurrence rate;5-year overall survival rate;treatment-related adverse reactions;—

Countries

China

Contacts

Public ContactTang Yanlai

The First Affiliated Hospital of Sun Yat-sen University

tangylai@mail.sysu.edu.cn+86 156 2620 2579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026